Alphatec Holdings, Inc. (ATEC)
| Market Cap | 1.36B -44.2% |
| Revenue (ttm) | 815.05M +19.5% |
| Net Income | -109.99M |
| EPS | -0.72 |
| Shares Out | 154.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 670,242 |
| Open | 8.77 |
| Previous Close | 8.99 |
| Day's Range | 8.60 - 8.92 |
| 52-Week Range | 6.82 - 23.29 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 15.79 (+79.94%) |
| Earnings Date | Oct 29, 2026 |
About ATEC
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-o... [Read more]
Financial Performance
In 2025, Alphatec Holdings's revenue was $764.16 million, an increase of 24.95% compared to the previous year's $611.56 million. Losses were -$143.36 million, -11.57% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ATEC stock is "Strong Buy." The 12-month stock price target is $15.79, which is an increase of 79.94% from the latest price.
News
Alphatec Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
Procedural volumes and surgeon adoption remain strong, supporting robust revenue and EBITDA growth targets through 2027. Product innovation in Valence, EOS Insight, and biologics, along with disciplined cost management, underpin confidence in meeting long-term financial goals.
Alphatec price target raised to $16 from $15 at UBS
UBS raised the firm’s price target on Alphatec (ATEC) to $16 from $15 and keeps a Buy rating on the shares.
Alphatec price target raised to $13 from $11 at TD Cowen
TD Cowen raised the firm’s price target on Alphatec (ATEC) to $13 from $11 and keeps a Buy rating on the shares. The firm said . 2Q was much better…
Alphatec price target lowered to $19 from $23 at Canaccord
Canaccord lowered the firm’s price target on Alphatec (ATEC) to $19 from $23 and keeps a Buy rating on the shares. The firm said they posted a solid Q2 with…
Alphatec price target raised to $12 from $11 at BMO Capital
BMO Capital raised the firm’s price target on Alphatec (ATEC) to $12 from $11 and keeps an Outperform rating on the shares. The company’s Q2 beat-and-raise, strong procedure and surgeon…
Alphatec Holdings Earnings Call Transcript: Q2 2026
Q2 saw 15% revenue growth to $214M, with surgical up 17% and strong surgeon/user adoption. Adjusted EBITDA rose 53% to $36M (17% margin), and guidance for full-year EBITDA was raised to $140M. EOS and new technologies are driving future growth, with robust international expansion.
Alphatec Holdings Slides: Q2 2026
Alphatec Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Alphatec Holdings Earnings release: Q2 2026
Alphatec Holdings released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Alphatec Holdings Quarterly report: Q2 2026
Alphatec Holdings has published its Q2 2026 quarterly earnings report on August 4, 2026.
ATEC Reports Second Quarter Financial Results
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced ...
Alphatec initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of Alphatec (ATEC) with a Buy rating and $15 price target The firm sees modest spine market growth ahead, with surgeon and hospital feedback…
Alphatec initiated with a Buy at UBS
UBS analyst Patrick Wood initiated coverage of Alphatec (ATEC) with a Buy rating and $15 price target
ATEC Announces Participation in Upcoming Investor Conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that managemen...
Alphatec initiated with an Overweight at Stephens
Stephens initiated coverage of Alphatec (ATEC) with an Overweight rating and $15 price target The firm views Alphatec as a “disruptor” that is reshaping how spine surgery is performed “within…
ATEC to Report Second Quarter 2026 Financial Results on August 4, 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will r...
Alphatec initiated with an Outperform at BMO Capital
BMO Capital analyst Vik Chopra initiated coverage of Alphatec (ATEC) with an Outperform rating and $11 price target A Q1 slowdown, driven by EOS lumpiness and procedure mix, was not…
Alphatec price target lowered to $13 from $16 at Stifel
Stifel lowered the firm’s price target on Alphatec (ATEC) to $13 from $16 and keeps a Buy rating on the shares. Concerns over a potential 2026 Surgical revenue guidance cut…
Alphatec Holdings Transcript: Bank of America Global Healthcare Conference 2026
Spine surgery market penetration remains low, but rapid growth is driven by clinical innovation, procedural adoption, and technology integration. International expansion and operational leverage have led to positive EBITDA, improved cash flow, and strong financial guidance for 2026.
Alphatec Holdings Slides: FY 2026
Alphatec Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 12, 2026.
Alphatec price target lowered to $24 from $27 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on Alphatec (ATEC) to $24 from $27 and keeps an Overweight rating on the shares.
Alphatec price target lowered to $24 from $27 at Barclays
Barclays lowered the firm’s price target on Alphatec (ATEC) to $24 from $27 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1…
Alphatec price target lowered to $23 from $25 at Canaccord
Canaccord lowered the firm’s price target on Alphatec (ATEC) to $23 from $25 and keeps a Buy rating on the shares. The firm said they posted an uncharacteristic miss in…
Alphatec price target lowered to $16 from $24 at JPMorgan
JPMorgan lowered the firm’s price target on Alphatec (ATEC) to $16 from $24 and keeps an Overweight rating on the shares.
Alphatec price target lowered to $11 from $20 at TD Cowen
TD Cowen lowered the firm’s price target on Alphatec (ATEC) to $11 from $20 and keeps a Buy rating on the shares. The firm said sales disappointed, particularly EOS, but…
Alphatec price target lowered to $15 from $25 at Lake Street
Lake Street analyst Ben Haynor lowered the firm’s price target on Alphatec (ATEC) to $15 from $25 and keeps a Buy rating on the shares. While “sell reflexes are strong…